Opiant signs contract with BARDA to accelerate OPTN003 product development

Image: Opiant Pharmaceuticals has signed contract with BARDA to accelerate development of nasal nalmefene to treat opioid overdose. Photo: courtesy of Baitong333 / FreeDigitalPhotos.net.